An Open Label Study of the Effect of Adjuvant Treatment With Capecitabine in Combination With Oxaliplatin on Disease-free Survival in Patients With Stage III Colon Cancer
Latest Information Update: 12 Jul 2016
Price :
$35 *
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin
- Indications Colon cancer
- Focus Therapeutic Use
- Sponsors Roche
- 31 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2015 Planned End Date changed from 1 May 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
- 01 Jul 2015 Planned primary completion date changed from 1 May 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.